Implicity Continues Rapid Growth and Expansion with Hiring of Two New Senior Leaders

Implicity, a leader in remote patient monitoring and cardiac data management solutions, announced its continued growth with the appointment of two new senior-level executives. Vanessa Joyce was named the Company’s new Vice President of Sales for North America, and Megan Grosz was appointed Global Head of Marketing and Communications.

“We’re thrilled to welcome these two impressive leaders. Both Vanessa and Megan bring a wealth of industry knowledge to support our rapid global expansion, particularly in the U.S. where we see a dramatic rise in remote patient monitoring,” said Dr. Arnaud Rosier, Electrophysiologist, CEO, and Co-founder of Implicity.

Vanessa Joyce comes to Implicity with more than 30 years of experience in MedTech marketing and clinical aspects of the Cardiac, Heart Failure, and Electrophysiology industries. Prior to joining the Company, she served as the area director of sales for Rhythm Management Group. She also held sales leadership roles at Philips Healthcare, Medtronic and St. Jude Medical.

Recommended AI News: Delinea Reduces Ransomware Risk for Customers Using Azure AD Government, Makes Secure Remote Access More Seamless

“I’m excited to apply my expertise and experience to establish Implicity as the primary CIED remote monitoring software solution,” said Joyce. “We are building an extraordinary sales force to bring this unparalleled technology to providers and revolutionize care for CIED patients. This solution will help drive the adoption of RPM by helping cardiologists, electrophysiologists, and their teams manage the growing volume of data and false alerts that are becoming so difficult and time-consuming to review.”

To help communicate the unique benefits of Implicity’s automated cardiac remote monitoring platform, Megan Grosz is joining Implicity as Head of Global Marketing and Communications. She will leverage her sales and business development success to drive increased brand awareness and reach for Implicity with an emphasis on the recently FDA-approved AI algorithm that analyzes ECG episodes from Implantable Loop Recorders (ILRs). According to a study published in the European Heart Journal, applying the machine learning algorithm to ECG data collected by Medtronic’s ICMs decreased the false positive rate by nearly 80%.

Recommended AI News: Borrego’s Web-Based O&M Customer Portal Provides Real-Time Actionable Insights into Solar Project Operations

Grosz previously served as the Director of Sales and Marketing at Omega Medical Imaging, a manufacturer of AI-enabled, image-guided interventional imaging systems for cardiology, electrophysiology, interventional radiology, and therapeutic endoscopy.

“There is a growing appetite for intelligent, cloud-based solutions that can improve the productivity and efficiency of care delivery. By handling data-intensive tasks and reducing false positive alerts, Implicity’s AI-powered platform can make a real difference in the lives of healthcare providers. All of this translates into better outcomes for patients,” said Grosz. “I look forward to sharing this unique solution with providers around the world.”

Recommended AI News: Husqvarna Affirms its Commitment to Autonomous Mowing and Leadership in Robotics as a Service (RaaS) with Expanded Investment in Robin Autopilot

[To share your insights with us, please write to sghosh@martechseries.com]